Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
wHbXxNeUW2a8uPYz
